Genmab A/S Share Price

Equities

GMAB

DK0010272202

Biotechnology & Medical Research

Market Closed - Nasdaq Copenhagen 08:29:33 22/05/2024 pm IST 5-day change 1st Jan Change
2,055 DKK +2.65% Intraday chart for Genmab A/S -0.48% -4.64%

Financials

Sales 2024 * 19.8B 2.87B 239B Sales 2025 * 23.62B 3.43B 285B Capitalization 133B 19.25B 1,603B
Net income 2024 * 4.67B 678M 56.45B Net income 2025 * 6.61B 960M 79.91B EV / Sales 2024 * 5.43 x
Net cash position 2024 * 25.1B 3.64B 303B Net cash position 2025 * 32.35B 4.69B 391B EV / Sales 2025 * 4.25 x
P/E ratio 2024 *
30.2 x
P/E ratio 2025 *
21.7 x
Employees 2,286
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.5%
More Fundamentals * Assessed data
Dynamic Chart
1 day+2.65%
1 week-0.48%
Current month+5.03%
1 month+1.23%
3 months+2.90%
6 months-4.42%
Current year-4.64%
More quotes
1 week
1 990.00
Extreme 1990
2 068.00
1 month
1 915.50
Extreme 1915.5
2 088.00
Current year
1 825.00
Extreme 1825
2 227.00
1 year
1 825.00
Extreme 1825
2 896.00
3 years
1 825.00
Extreme 1825
3 327.00
5 years
1 082.50
Extreme 1082.5
3 327.00
10 years
204.80
Extreme 204.8
3 327.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 63 01/99/01
Director of Finance/CFO 46 01/07/01
Chief Operating Officer 53 23/20/23
Members of the board TitleAgeSince
Chairman 63 01/17/01
Director/Board Member 73 01/03/01
Director/Board Member 64 01/16/01
More insiders
Date Price Change Volume
22/24/22 2,055 +2.65% 144,359
21/24/21 2,002 -1.91% 104,489
17/24/17 2,041 +0.74% 71,028
16/24/16 2,026 -1.89% 147,504
15/24/15 2,065 +1.98% 81,575

Delayed Quote Nasdaq Copenhagen, May 22, 2024 at 08:29 pm IST

More quotes
Genmab A/S specializes in the research and development of human and therapeutic antibodies intended for treating cancers, infectious diseases, rheumatoid arthritis, etc. Net sales break down by type of income as follows: - royalties (83.2%); - income from research and development (12.4%); - other (4.4%): primarily income from partnership agreement. At the end of 2023, the group had a portfolio of more than 20 products in clinical development phase and 20 in preclinical development phase. Denmark accounts for all net sales.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
23
Last Close Price
2,055 DKK
Average target price
2,466 DKK
Spread / Average Target
+19.99%
Consensus